EMEA-001119-PIP03-19-M02
Key facts
| Invented name |
|
| Active substance |
Lenvatinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0154/2022
|
| PIP number |
EMEA-001119-PIP03-19-M02
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer, follicular thyroid cancer and osteosarcoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Eisai GmbH
E-mail: EUMedInfo@eisai.net |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|